Ligand Pharmaceuticals (LGNYZ) EBIAT (2016 - 2025)
Historic EBIAT for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $117.3 million.
- Ligand Pharmaceuticals' EBIAT rose 173515.06% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 737.56%. This contributed to the annual value of -$4.0 million for FY2024, which is 10749.18% down from last year.
- Ligand Pharmaceuticals' EBIAT amounted to $117.3 million in Q3 2025, which was up 173515.06% from $4.8 million recorded in Q2 2025.
- Ligand Pharmaceuticals' 5-year EBIAT high stood at $117.3 million for Q3 2025, and its period low was -$51.9 million during Q2 2024.
- In the last 5 years, Ligand Pharmaceuticals' EBIAT had a median value of $4.8 million in 2025 and averaged $10.2 million.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 236685.59% in 2024, then surged by 173515.06% in 2025.
- Ligand Pharmaceuticals' EBIAT (Quarter) stood at -$5.4 million in 2021, then plummeted by 222.78% to -$17.5 million in 2022, then surged by 204.02% to $18.2 million in 2023, then plummeted by 270.93% to -$31.1 million in 2024, then surged by 477.23% to $117.3 million in 2025.
- Its EBIAT was $117.3 million in Q3 2025, compared to $4.8 million in Q2 2025 and -$42.5 million in Q1 2025.